A STUDY TO ANALYZE THE OCCURRENCE OF TRANSFORMATION FROM MYELODYSPLASTIC SYNDROME TO ACUTE MYELOID LEUKEMIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WHO RECEIVED REVLIMID® 5 MG CAPSULES AND WHO ARE CONTINUING OR NO LONGER CONTINUING REVLIMID TREATMENT: